Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:05pm, Thursday, 25'th Jun 2020
Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
08:05pm, Monday, 22'nd Jun 2020
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of
Leap Therapeutics (NASDAQ:LPTX) Shares Gap Down to $2.04
02:20am, Sunday, 21'st Jun 2020
Leap Therapeutics Inc (NASDAQ:LPTX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $2.06, but opened at $2.04. Leap Therapeutics shares last traded
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
01:00pm, Thursday, 18'th Jun 2020
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its co
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
08:01pm, Wednesday, 17'th Jun 2020
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of
Apogenix to Present at AACR Virtual Annual Meeting II | | IT Business Net
09:10am, Wednesday, 17'th Jun 2020
HEIDELBERG, GERMANY / ACCESSWIRE / June 17, 2020 / Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the AACR Virtual Annual
Company News for Jun 15, 2020
01:58pm, Monday, 15'th Jun 2020
Companies in the news are: EMAN, LPTX, VISL, CLPS
Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session
12:32pm, Monday, 15'th Jun 2020
Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Hedge Funds Have Never Been This Bullish On LEAP THERAPEUTICS, INC. (LPTX)
03:19pm, Friday, 12'th Jun 2020
In this article we will check out the progression of hedge fund sentiment towards LEAP THERAPEUTICS, INC. (NASDAQ:LPTX) and determine whether it is a good investment right now. We at Insider Monkey li
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
11:30am, Friday, 12'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 11) * ADC Therapeutics SA (NYSE: ADCT) * Applied Molecul
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
08:06pm, Thursday, 11'th Jun 2020
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has gra
Leap Therapeutics Announces Changes to Virtual Format and Time for 2020 Annual Meeting of Stockholders
08:05pm, Thursday, 11'th Jun 2020
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related
Analyst Estimates: Here's What Brokers Think Of Leap Therapeutics, Inc. (NASDAQ:LPTX) After Its First-Quarter Report
02:23pm, Saturday, 16'th May 2020
Leap Therapeutics, Inc. (NASDAQ:LPTX) missed earnings with its latest quarterly results, disappointing...
Leap Therapeutics Reports First Quarter 2020 Financial Results
11:00am, Thursday, 14'th May 2020
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31,
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
11:00am, Thursday, 23'rd Apr 2020
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced updated clinical data from its ongoing Phase 2 clinical
